NMS·Healthcare·$53M·#361 / 520 in Healthcare
MGX Metagenomi Therapeutics, Inc.
32HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY33
VALUATION94
GOVERNANCE88
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-51.8%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
6 months
9
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
25.6%
79
< 25% strong
Price / Sales
Market cap relative to trailing revenue
2.1x
94
< 3x strong
Rule of 40
Growth rate plus operating margin
-433
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
19.3%
84
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+0.7%
96
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE MGX WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when MGX's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.